Trousseau University Hospital, Faculty of Medicine, François Rabelais University, Tours, France.
Trousseau University Hospital, Faculty of Medicine, François Rabelais University, Tours, France.
J Am Coll Cardiol. 2018 Apr 10;71(14):1528-1536. doi: 10.1016/j.jacc.2018.01.076.
Transcatheter left atrial appendage (LAA) occlusion is an alternative strategy for stroke prevention in patients with atrial fibrillation (AF).
This study sought to determine the incidence, predictors, and prognosis of thrombus formation on devices in patients with AF who were treated with LAA closure.
The study retrospectively analyzed data from patients treated with 2 LAA closure devices seen in 8 centers in France from February 2012 to January 2017.
A total of 469 consecutive patients with AF underwent LAA closure (272 Watchman devices [Atritech, Boston Scientific, Natick, Massachusetts] and 197 Amplatzer devices [St. Jude Medical, Minneapolis, Minnesota]). Mean follow-up was 13 ± 13 months, during which 339 (72.3%) patients underwent LAA imaging at least once. There were 98 major adverse events (26 thrombi on devices, 19 ischemic strokes, 2 transient ischemic attacks, 18 major hemorrhages, 33 deaths) recorded in 89 patients. The incidence of device-related thrombus in patients with LAA imaging was 7.2% per year. Older age (hazard ratio [HR]: 1.07 per 1-year increase; 95% confidence interval [CI]: 1.01 to 1.14; p = 0.02) and history of stroke (HR: 3.68; 95% CI: 1.17 to 11.62; p = 0.03) were predictors of thrombus formation on the devices, whereas dual antiplatelet therapy (HR: 0.10; 95% CI: 0.01 to 0.76; p = 0.03) and oral anticoagulation at discharge (HR: 0.26; 95% CI: 0.09 to 0.77; p = 0.02) were protective factors. Thrombus on the device (HR: 4.39; 95% CI: 1.05 to 18.43; p = 0.04) and vascular disease (HR: 5.03; 95% CI: 1.39 to 18.23; p = 0.01) were independent predictors of ischemic strokes and transient ischemic attacks during follow-up.
Thrombus formation on the device is not uncommon in patients with AF who are treated by LAA closure. Such events are strongly associated with a higher risk of ischemic stroke during follow-up. (REgistry on Real-Life EXperience With Left Atrial Appendage Occlusion [RELEXAO]; NCT03279406).
经导管左心耳(LAA)封堵术是预防房颤(AF)患者卒中的一种替代策略。
本研究旨在确定接受 LAA 封堵治疗的 AF 患者中,器械上血栓形成的发生率、预测因素和预后。
该研究回顾性分析了 2012 年 2 月至 2017 年 1 月法国 8 个中心使用 2 种 LAA 封堵装置治疗的患者数据。
共 469 例连续 AF 患者接受了 LAA 封堵术(272 个 Watchman 装置[雅培公司,波士顿科学公司,马萨诸塞州纳提克]和 197 个 Amplatzer 装置[圣犹达医疗公司,明尼苏达州明尼阿波利斯])。平均随访 13±13 个月,在此期间,339 例(72.3%)患者至少进行了一次 LAA 影像学检查。89 例患者共记录了 98 例主要不良事件(26 例器械相关血栓形成、19 例缺血性卒、2 例短暂性脑缺血发作、18 例大出血、33 例死亡)。LAA 影像学检查的患者中,器械相关血栓形成的发生率为每年 7.2%。年龄较大(风险比[HR]:每增加 1 岁为 1.07;95%置信区间[CI]:1.01 至 1.14;p=0.02)和既往卒中史(HR:3.68;95%CI:1.17 至 11.62;p=0.03)是器械上血栓形成的预测因素,而双联抗血小板治疗(HR:0.10;95%CI:0.01 至 0.76;p=0.03)和出院时的口服抗凝治疗(HR:0.26;95%CI:0.09 至 0.77;p=0.02)是保护因素。器械上血栓形成(HR:4.39;95%CI:1.05 至 18.43;p=0.04)和血管疾病(HR:5.03;95%CI:1.39 至 18.23;p=0.01)是随访期间缺血性卒中和短暂性脑缺血发作的独立预测因素。
在接受 LAA 封堵治疗的 AF 患者中,器械上血栓形成并不罕见。此类事件与随访期间更高的缺血性卒风险密切相关。(真实世界左心耳封堵术经验登记研究[RELEXAO];NCT03279406)。